Publications by authors named "E Carcereny"
Purpose: The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously.
Experimental Design: Next-generation sequencing (Guardant360) was conducted in serial plasma samples.
Objectives: Lung Cancer (LC) is a multifactorial disease for which the role of genetic susceptibility has become increasingly relevant. Our aim was to use artificial intelligence (AI) to analyze differences between patients with LC based on family history of cancer (FHC).
Materials And Methods: From August 2016 to June 2020 clinical information was obtained from Thoracic Tumors Registry (TTR), a nationwide database sponsored by the Spanish Lung Cancer Group.
Background: Early detection is crucial to improve lung cancer survival rates. Delays in diagnosis might negatively impact the prognosis of the disease. This study aims to analyze the diagnostic delay in lung cancer patients and describe if there is an association between delay and survival.
View Article and Find Full Text PDFArticle Synopsis
- The JAVELIN Lung 101 trial tested avelumab, an immune checkpoint inhibitor, alongside lorlatinib or crizotinib (tyrosine kinase inhibitors) in advanced non-small cell lung cancer (NSCLC).
- The study aimed to determine the maximum tolerated dose (MTD) and evaluate the treatment's effectiveness based on patient response rates, focusing on dose-limiting toxicities (DLTs).
- Results showed that avelumab with lorlatinib was manageable with a response rate of 52%, while avelumab with crizotinib was less feasible, with a lower response rate of 25% and high DLT incidence.
Background: Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at lower doses; therefore, we evaluated the efficacy and safety of sotorasib 960 mg and 240 mg.
Methods: In this phase 2, randomized, open-label study, adults with KRAS G12C-mutated advanced NSCLC received sotorasib 960 mg or 240 mg once daily.